Privacy preference

MEDtalks would like to keep you informed about the content that is most relevant to you. Click here for more information.

Quarterly Focus on GU | Bladder Cancer

Publications in peer-reviewed journals are a major source for keeping up with the latest developments in your field. However, you may not always have sufficient time to study (difficult) publications thoroughly and to determine the impact on your clinical practice. To support you, MEDtalks Oncology has developed a new program format: the Quarterly Focus. This innovative program brings an expert panel and authors of relevant, selected publications together to explain and discuss the new data.

In this third episode of the Quarterly Focus on Genitourinary Cancer, two pivotal, international publications on Bladder Cancer from the past few months will be clarified by one of the authors and will be thoroughly discussed by an expert panel including the author. The program will give you the possibility to gain more insight into the selected publications.

The expert panel consist of:
Michiel van der Heijden, MD, PhD - medical oncologist, Netherlands Cancer Institute, Amsterdam
Prof. Fred Witjes, MD -  urologist, Radboudumc, Nijmegen
Sjoukje Oosting, MD, PhD - medical oncologist, UMCG, Groningen


Speaker: Prof. Dipen Parekh, MD – urologist at University of Miami Health System in Miami, USA
Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial
Lancet 391, 2018

Speaker: Michiel van der Heijden, MD, PhD, medical oncologist, Netherlands Cancer Institute, Amsterdam, The Netherlands
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial
Lancet 391, 2017

  • Sponsors

    This program is editorially independent and is financially supported by:

Related items